All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Symposium | Introduction to T-cell engagers and general mechanism of action

Apr 9, 2024
Learning objective: After reading this article, learners will be able to describe novel therapeutic targets in MM and explain the mechanisms of action for new agents in MM.

Bookmark this article

The Multiple Myeloma Hub virtual symposium held on March 11, 2024, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learnings from 2023,” was chaired by Sagar Lonial and featured expert presentations from Naresh Bumma, Amrita Krishnan, and Sergio Giralt.

Lonial opened with a welcome and introduction to T-cell-engaging bispecific antibodies and their mechanisms of action in multiple myeloma (Figure 1). Lonial also discusses the expanding treatment options in relapsed/refractory disease (Figure 2), offering insight into the targets for bispecific antibody action and their expression on myeloma cells.

Figure 1. T-cell directed bispecific antibodies: Mechanism of action* 

c, fragment crystallizable region; FcRH5, Fc receptor-homolog 5; GPRC5D, G protein–coupled receptor class C group 5 member D; MM, multiple myeloma.
 *Adapted from Van de Donk N, et al.1


Figure 2. Treatment options for relapsed/refractory disease in multiple myeloma* 

BsAb, bispecific antibody; IMiD, immunomodulatory agent; mAb, monoclonal antibody; MoA, mechanism of action; PI, proteosome inhibitor.
*Data from Bhatt, et al.2 and Gahvari, et al.3

This independent medical activity was funded by Janssen and Bristol Myers Squibb. All content was developed independently by the faculty. The funders were allowed no influence on the content of this activity.

  1. Van de Donk N, O’Neill C, Ruijter M, et al. T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA. Curr Opin Oncol. 2023;35(6):601-611. DOI: 1097/CCO.0000000000000983
  2. Bhatt P, Kloock C, Comenzo R. Relapsed/refractory multiple myeloma: A review of available therapies and clinical scenarios encountered in myeloma relapse. Curr Oncol. 2023;30(2): 2322-2347. DOI: 3390/curroncol30020179
  3. Gahvari Z and Callander N. The management of relapsed and refractory multiple myeloma. Oncology (Williston Park). 2023;37(4):164-174. DOI: 46883/2023.25920991
  4. Smith E, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):eaau7746. DOI: 1126/scitranslmed.aau7746
  5. Jiang D, Huang H, Qin H, et al. Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma. Nat Commun. 2023;14:3642. DOI: 1038/s41467-023-39395-4


Subscribe to get the best content related to multiple myeloma delivered to your inbox